Key Takeaways
- • The primary source, a STAT Readout newsletter dated November 12, 2026, is headlined around Blackstone backing Pfizer's bet on a monthly obesity treatment, but the full story is behind the STAT+ paywall and its substance is not available in the source text.
- • Bristol Myers Squibb restructured its R&D leadership, giving Chief Medical Officer Cristian Massacesi the additional title of head of R&D, with chief of research Robert Plenge departing in March.
- • According to Reuters, the FDA has shelved the Commissioner's National Priority Voucher program.
- • The Senate health committee will vote next Wednesday on Heidi Overton's nomination to lead the FDA, and Chair Bill Cassidy of Louisiana is undecided and has called Overton's role in shaping Trump administration vaccine policy "almost disqualifying," per STAT's Margaret Manto.
- • A single Republican defection could sink the nomination if every Democrat votes against her.
Summary
STAT's biotech Readout newsletter flagged a Blackstone investment tied to Pfizer's pursuit of a monthly obesity treatment, the headline's central news item. The accessible source text, however, contains only the headline and a paywall notice for the STAT+ exclusive, so the deal terms, investment size, and clinical details cannot be confirmed from this material.
Other items in the newsletter covered leadership changes at Bristol Myers Squibb. The company made changes to its research and development structure, with Chief Medical Officer Cristian Massacesi taking the additional title of head of R&D. Robert Plenge, Bristol's chief of research, will leave the company in March. Separately, according to Reuters, the FDA has shelved the Commissioner's National Priority Voucher program.
The newsletter also highlighted a contested FDA leadership nomination. The Senate health committee will vote next Wednesday on Heidi Overton's nomination to lead the agency. Committee Chair Bill Cassidy of Louisiana has said he is undecided and has described Overton's role in shaping Trump administration vaccine policies as "almost disqualifying," according to STAT's Margaret Manto. Because Republicans are not unified in support, a single Republican defection could defeat the nomination if all Democrats vote against it.
Other items in the newsletter covered leadership changes at Bristol Myers Squibb. The company made changes to its research and development structure, with Chief Medical Officer Cristian Massacesi taking the additional title of head of R&D. Robert Plenge, Bristol's chief of research, will leave the company in March. Separately, according to Reuters, the FDA has shelved the Commissioner's National Priority Voucher program.
The newsletter also highlighted a contested FDA leadership nomination. The Senate health committee will vote next Wednesday on Heidi Overton's nomination to lead the agency. Committee Chair Bill Cassidy of Louisiana has said he is undecided and has described Overton's role in shaping Trump administration vaccine policies as "almost disqualifying," according to STAT's Margaret Manto. Because Republicans are not unified in support, a single Republican defection could defeat the nomination if all Democrats vote against it.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.